We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alexion Pharmaceuticals, Inc.’s third-quarter 2016 earnings (including stock-based compensation expense) of $1.03 cents per share missed the Zacks Consensus Estimate of $1.04.
Revenues, on the other hand, soared 20.1% year over year to $799 million. The impact of currency headwind on the top line was 2.5% ($16 million). The majority of the company’s revenues were generated by Soliris. The figure also surpassed the Zacks Consensus Estimate of $784 million.
Soliris Drives Growth
Soliris sales were up 9.6% to $729 million driven by steady growth in patients in both the indications – paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Strensiq and Kanuma contributed $61 million and $9 million, respectively, to quarterly revenues.
Operating expenses (including stock-based compensation expense, and upfront and milestone payments related to license and collaboration deals, and other special items) increased. Research and development (R&D) expenses were up 18.1%, while selling, general and administrative (SG&A) expenses climbed 8.3%.
Guidance
Alexion has revised its guidance for total revenue and adjusted earnings for 2016. The company now expects both revenues and adjusted earnings per share to be at the high end of the previously guided ranges of $3.05–$3.1 billion and $4.50–$4.65, respectively.
On the other hand, the company continues to expect Soliris revenues in the range of $2.83–$2.87 billion. Revenues from the metabolic franchise, comprising Kanuma and Strensiq, are now expected in the range $225–$235 million (previous guidance: $200–$220 million).
The company expects R&D expenses and SG&A expenses to be around $680–$690 million (previous expectation: high end of the $650–$680 million band) and $790–$810 million (prior expectation: high end of the $760–$790 million band), respectively.
Pipeline Update
The company continues to progress with the candidates in its pipeline. Currently, the company is evaluating Soliris in a couple of phase III studies – PREVENT, for the treatment of relapsing neuromyelitis optica spectrum disorder; and PROTECT, for the treatment of delayed graft function. Results from the PROTECT study are expected in the fourth quarter of 2016.
Moreover, Alexion plans to file regulatory submissions for Soliris for the treatment of refractory generalized myasthenia gravis in both the U.S. and the EU in the first quarter of 2017.
Alexion’s third-quarter results were mixed, with the company missing bottom-line estimates but beating revenue expectations. We expect growth at Alexion to continue being driven by Soliris. Launch of new products – Strensiq and Kanuma – should boost revenues and eventually reduce the company’s dependence on Soliris for growth. We are also impressed by Alexion’s efforts to develop its pipeline.
BioMarin’s loss estimates have narrowed from 28 cents to 25 cents for 2016 and from $1.16 to $1.11 for 2017 over the last 60 days.
Innoviva’s estimates have increased from 60 cents to 62 cents for 2016 and from $1.14 to $1.15 for 2017 over the last 60 days.
Geron has posted a positive earnings surprise in each of the four trailing quarters, bringing the average beat to 20.78%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand.Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Alexion (ALXN) Q3 Earnings Lag, Revenues Tops; Lifts View
Alexion Pharmaceuticals, Inc.’s third-quarter 2016 earnings (including stock-based compensation expense) of $1.03 cents per share missed the Zacks Consensus Estimate of $1.04.
Revenues, on the other hand, soared 20.1% year over year to $799 million. The impact of currency headwind on the top line was 2.5% ($16 million). The majority of the company’s revenues were generated by Soliris. The figure also surpassed the Zacks Consensus Estimate of $784 million.
Soliris Drives Growth
Soliris sales were up 9.6% to $729 million driven by steady growth in patients in both the indications – paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Strensiq and Kanuma contributed $61 million and $9 million, respectively, to quarterly revenues.
Operating expenses (including stock-based compensation expense, and upfront and milestone payments related to license and collaboration deals, and other special items) increased. Research and development (R&D) expenses were up 18.1%, while selling, general and administrative (SG&A) expenses climbed 8.3%.
Guidance
Alexion has revised its guidance for total revenue and adjusted earnings for 2016. The company now expects both revenues and adjusted earnings per share to be at the high end of the previously guided ranges of $3.05–$3.1 billion and $4.50–$4.65, respectively.
On the other hand, the company continues to expect Soliris revenues in the range of $2.83–$2.87 billion. Revenues from the metabolic franchise, comprising Kanuma and Strensiq, are now expected in the range $225–$235 million (previous guidance: $200–$220 million).
The company expects R&D expenses and SG&A expenses to be around $680–$690 million (previous expectation: high end of the $650–$680 million band) and $790–$810 million (prior expectation: high end of the $760–$790 million band), respectively.
Pipeline Update
The company continues to progress with the candidates in its pipeline. Currently, the company is evaluating Soliris in a couple of phase III studies – PREVENT, for the treatment of relapsing neuromyelitis optica spectrum disorder; and PROTECT, for the treatment of delayed graft function. Results from the PROTECT study are expected in the fourth quarter of 2016.
Moreover, Alexion plans to file regulatory submissions for Soliris for the treatment of refractory generalized myasthenia gravis in both the U.S. and the EU in the first quarter of 2017.
ALEXION PHARMA Price and EPS Surprise
ALEXION PHARMA Price and EPS Surprise | ALEXION PHARMA Quote
Our Take
Alexion’s third-quarter results were mixed, with the company missing bottom-line estimates but beating revenue expectations. We expect growth at Alexion to continue being driven by Soliris. Launch of new products – Strensiq and Kanuma – should boost revenues and eventually reduce the company’s dependence on Soliris for growth. We are also impressed by Alexion’s efforts to develop its pipeline.
Zacks Rank & Key Picks
Alexion currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector include Innoviva, Inc. (INVA - Free Report) , BioMarin Pharmaceutical Inc. (BMRN - Free Report) and Geron Corp. (GERN - Free Report) . Both stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
BioMarin’s loss estimates have narrowed from 28 cents to 25 cents for 2016 and from $1.16 to $1.11 for 2017 over the last 60 days.
Innoviva’s estimates have increased from 60 cents to 62 cents for 2016 and from $1.14 to $1.15 for 2017 over the last 60 days.
Geron has posted a positive earnings surprise in each of the four trailing quarters, bringing the average beat to 20.78%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>